Robust IPO activity persists into late 2026, with 249 U.S. listings priced year-to-date through September 28 and fresh S-1/F-1 filings plus amendments continuing at a steady pace. Recent pricings such as ADARx Pharmaceuticals and multiple SPAC deals, alongside upcoming offerings from Oura and Accelevation Holdings, reflect sustained market access for smaller and mid-sized issuers. Larger candidates including Anthropic (targeting an October Nasdaq debut) and OpenAI (with reports of potential slippage) face valuation scrutiny and execution risks that could shift resolutions into 2027. Trader sentiment on these timelines incorporates equity market volatility, Treasury yield levels, and regulatory clearance pace, with Q4 catalysts likely to determine final 2026 outcomes.